Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis

BACKGROUND: CT-P10 is a biosimilar candidate of innovator rituximab (RTX) that demonstrated a comparable clinical profile to RTX in a phase I randomized controlled trial (RCT) in rheumatoid arthritis (RA) (ClinicalTrials.gov identifier: NCT01534884). OBJECTIVE: This open-label extension (OLE) study...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Won, Suh, Chang-Hee, Shim, Seung Cheol, Molina, Francisco Fidencio Cons, Jeka, Slawomir, Medina-Rodriguez, Francisco G., Hrycaj, Pawel, Wiland, Piotr, Lee, Eun Young, Shesternya, Pavel, Kovalenko, Volodymyr, Myasoutova, Leysan, Stanislav, Marina, Radominski, Sebastiao, Lim, Mie Jin, Choe, Jung-Yoon, Lee, Sang Joon, Lee, Sung Young, Kim, Sung Hwan, Yoo, Dae Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548826/
https://www.ncbi.nlm.nih.gov/pubmed/28600696
http://dx.doi.org/10.1007/s40259-017-0233-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548826/
https://www.ncbi.nlm.nih.gov/pubmed/28600696
http://dx.doi.org/10.1007/s40259-017-0233-6

Ejemplares similares